<DOC>
	<DOC>NCT02608411</DOC>
	<brief_summary>This study aims to assess the role of MET inhibitors as maintenance treatment in adult patients with extensive stage small cell lung cancer.</brief_summary>
	<brief_title>TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<criteria>Histologically confirmed extensivestage SCLC Disease control after the first line platinum/etoposide treatment ECOG performance status of 0 or 1 Measurable disease according to RECIST Version 1.1 criteria Adequate bone marrow, liver, and renal function. Formalin Fixed Paraffin Embedded (FFPE) or frozen tumor tissue material must be available. Resolution of any toxic effects of prior therapy according to NCI CTCAE, v 4.0 Full recovery from significant complications of the surgery If childbearing age, use of doublebarrier contraceptive measures, oral or abstaining from sexual intercourse during the study and up to 90 days after the last dose of chemotherapy Negative pregnancy test within 72 hours prior to the initiation of study treatment, if of childbearing potential Signed informed consent prior to beginning protocol specific procedures Patients must be available for treatment and followup Previous therapies with Tivantinib or other known cMET inhibitor Radiotherapy for target lesions and major surgical procedure within 4 weeks, prior to the inclusion in the study Palliative radiotherapy within 2 weeks prior to the inclusion in the study History of malignancy in the past five years, excluding basal cell the cervix, prostate cancer with a value of prostatespecific antigen &lt;0.2 ng / mL History of cardiac disease Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections Pregnant or lactating women or childbearing/reproductive potential not using adequate contraception Need for breastfeeding during or within 12 weeks of completion of the study Gastrointestinal disorders that may interfere with the absorption of Tivantinib Inability or unwillingness to swallow the complete doses of Tivantinib Any known contraindication to treatment and other significant comorbid conditions which could jeopardize participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>